Sandoz Canada launches two new biosimilars Ziextenzo® and Riximyo®

Sandoz Canada launches two new biosimilars Ziextenzo® and Riximyo®

Sandoz Canada reaches a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance (pCPA) for both medicines
Riximyo® is now covered in British Columbia and Ontario for patients in need of rituximabBoth Riximyo® and Ziextenzo® will be available in hospitals and cancer centres in addition to retail pharmacies across CanadaBOUCHERVILLE, Quebec, Aug. 19, 2020 (GLOBE NEWSWIRE) — Sandoz Canada Inc. announces it has reached a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance (pCPA) and launched Ziextenzo® (pegfilgrastim, reference biologic drug: Neulasta®) and Riximyo® (rituximab, reference biologic drug: Rituxan®) in Canadian hospitals and pharmacies. This follows the recent approval of the two biosimilars by Health Canada.
CBJ Newsmakers

Recommended
Aura Minerals Reports Significant Drill Intersections at Aranzazu Mine, Zacatecas, MexicoZoomerMedia Limited Announces Close of Sale of Assets of Darwin CX Inc.